Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cemiplimab in neoadjuvant cutaneous squamous cell carcinoma
NCT04154943Phase 2Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Mar 2020
- Primary completion
- Dec 2021
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Engineered Antibody Formats
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of cemiplimab in cutaneous squamous cell carcinoma (cSCC), sponsored by Regeneron Pharmaceuticals. Primary endpoint: Pathologic Complete Response (Independent Central Pathology Review) at 12 weeks. Started Mar 2020; status: completed.
02
Drugs
cemiplimab
03
Conditions
cutaneous squamous cell carcinoma (cSCC)
Beyond the preview
Go deeper on NCT04154943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04154943.